Tilray is looking at shareholder approval to increase its authorized share count to complete the MedMen transaction and to look at other strategic acquisitions. The company is targeting revenues of $4 billion by fiscal 2024. To put that in context, analysts don't expect Tilray to post $1 billion in revenues even by fiscal 2023.